FDA approves Cabometyx for hepatocellular carcinoma in patients previously treated with sorafenib.-Exelixis + Ipsen
Exelixis, Inc. announced that the FDA approved Cabometyx (cabozantinib) tablets for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. HCC is the most common form of liver cancer and the fastest-rising cause of cancer-related death in the U.S.
The FDA�s approval of Cabometyx was based on results from the CELESTIAL phase III pivotal trial of Cabometyx for patients with advanced HCC who received prior sorafenib. Cabometyx demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) versus placebo.
On November 15, 2018, Exelixis� partner Ipsen received approval from the European Commission for Cabomeytyx tablets as a monotherapy for HCC in adults who have previously been treated with sorafenib.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins